Perales-Afán Juan José, Aparicio-Pelaz Diego, Puente-Lanzarote Juan José, Fabre Marta
Clinical Biochemistry Department, University Hospital Lozano Blesa, Zaragoza, Spain.
Institute for health research de Aragón, Zaragoza, Spain.
Biochem Med (Zagreb). 2025 Jun 15;35(2):020707. doi: 10.11613/BM.2025.020707.
25-hydroxyvitamin D (25-OH-D) is essential for calcium homeostasis and bone health, with increasing evidence suggesting associations with non-skeletal diseases. However, the lack of consensus on optimal concentrations and laboratory variability has led to clinical uncertainty and excessive testing. This study evaluates the impact of demand management strategies and revised cut-off points on test volumes, unperformed determinations, and cost savings.
A retrospective study (January 2015-May 2024) analyzed all 25-OH-D requests. Concentrations of 25-OH-D were measured using electrochemiluminescence assays on a Cobas C8000. An annual trend analysis of 25-OH-D test requests was performed to evaluate changes in demand. In 2018, vitamin D deficiency prevalence was assessed according to three cut-off values (75, 50 and 30 nmol/L). We assessed the impact of demand management rules, implemented in May 2022, to reduce unnecessary testing. The follow-up testing rate was calculated as the proportion of repeat tests within 12 months after determination.
There was 25-OH-D testing increased from 10,830 in 2015 to nearly 85,000 in 2023. Demand management strategies led to 12,406 rejections in 2022 (from May onwards), 16,809 in 2023, and 7566 in 2024 (until May), saving €85,600. Follow-up testing rates dropped from ~15% before 2022 to ~5% afterward. Lowering the deficiency threshold from 75 to 50 nmol/L reduced deficiency diagnoses from > 70% to < 50%; at 30 nmol/L, rates could drop to ~10-11%.
Demand management strategies effectively reduce unnecessary testing and healthcare costs. Establishing appropriate reference values prevents overestimation of vitamin D deficiency, optimizing clinical and economic outcomes.
25-羟维生素D(25-OH-D)对钙稳态和骨骼健康至关重要,越来越多的证据表明其与非骨骼疾病有关。然而,对于最佳浓度缺乏共识以及实验室检测结果的变异性导致了临床不确定性和过度检测。本研究评估了需求管理策略和修订后的临界值对检测量、未进行的检测以及成本节约的影响。
一项回顾性研究(2015年1月至2024年5月)分析了所有25-OH-D检测申请。使用Cobas C8000上的电化学发光法检测25-OH-D的浓度。对25-OH-D检测申请进行年度趋势分析以评估需求变化。2018年,根据三个临界值(75、50和30 nmol/L)评估维生素D缺乏患病率。我们评估了2022年5月实施的需求管理规则对减少不必要检测的影响。随访检测率计算为检测后12个月内重复检测的比例。
25-OH-D检测量从2015年的10830次增加到2023年的近85000次。需求管理策略在2022年(从5月起)导致12406次检测申请被拒,2023年为16809次,2024年(截至5月)为7566次,节省了85600欧元。随访检测率从2022年前的约15%降至之后的约5%。将缺乏阈值从75 nmol/L降至50 nmol/L,缺乏诊断率从>70%降至<50%;在30 nmol/L时,该比率可能降至约10 - 11%。
需求管理策略有效地减少了不必要的检测和医疗成本。建立适当的参考值可防止对维生素D缺乏的高估,优化临床和经济结果。